Free shipping on qualifying orders

Primary product image

A dual agonist of the GLP-1 and GIP receptors under clinical investigation for metabolic and weight regulation. Lyophilised powder, research grade. (Placeholder listing — specifications pending verification.)

Axion Peptides compounds are synthesised to pharmaceutical-grade specifications and verified by independent HPLC analysis prior to release.

Frequently asked questions

What is tirzepatide?

Tirzepatide is a synthetic peptide that acts as a dual agonist at the GLP-1 and GIP receptors. It is supplied as a lyophilized powder strictly for research use only.

How does tirzepatide differ from GLP-3 (retatrutide)?

Tirzepatide activates two receptors (GLP-1 and GIP); GLP-3/retatrutide adds a third (glucagon). The dual-agonist profile of tirzepatide is the most extensively characterized incretin combination in the current literature.

What is tirzepatide studied for in research?

Research applications include incretin receptor pharmacology, glucose regulation, insulin sensitivity, appetite signaling, and body-composition endpoints in rodent and in-vitro models.

What does the Certificate of Analysis verify?

Each lot includes a third-party COA verifying purity by HPLC (>=99%), identity by mass spectrometry, and net peptide content. The batch report is published on the product page.

How should tirzepatide be stored before reconstitution?

Keep the lyophilized powder sealed at -20 C, protected from light and moisture. After reconstitution with bacteriostatic water, refrigerate at 2-8 C and minimize freeze-thaw cycles.

Is tirzepatide FDA approved for the uses described here?

The research material supplied here is for laboratory use only and is not FDA approved for human or veterinary use, diagnostics, or therapeutics.